arrow
T

Takeshi Omori

Department of Gastroenterological Surgery
H指数:35
被引数:4,715

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early tumor shrinkage during first-line immune checkpoint inhibitor–based chemotherapy is associated with progression-free survival in measurable unresectable gastric cancer

一线免疫检查点抑制剂为基础化疗期间早期肿瘤缩小与可测量不可切除胃癌的无进展生存期相关

2026-09-180
OAAI
Primary outcomes of a phase II trial of laparoscopic/robotic total gastrectomy with spleen-preserving splenic hilar dissection for locally advanced proximal gastric cancer involving the greater curvature (JCOG1809)

局部晚期近端胃癌伴大弯受侵保脾脾门清扫腹腔镜/机器人全胃切除术II期试验的主要结果(JCOG1809)

2026-08-240
PRE
Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis

佐立倍单抗诱导的胃黏膜损伤和低白蛋白血症:一项机制导向的临床分析

2026-07-200
PRE
Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary

纳武利尤单抗联合化疗在亚洲晚期或复发性胃或胃食管结合部癌患者中的应用(ATTRACTION-4研究):简明语言摘要

2026-03-010
OAAI
Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

术前吉西他滨/ Nab-紫杉醇联合放射治疗可切除边缘胰腺癌:与单独使用吉西他滨的术前放化疗比较分析

2026-02-010
OAAI
A single-center retrospective study of conversion surgery in stage IV gastric cancer: association with immune checkpoint inhibitor-based chemotherapy

单中心回顾性研究:IV期胃癌转化手术与基于免疫检查点抑制剂化疗的相关性

2026-01-011
PRE
An Exploratory Randomized Controlled Trial Comparing Ultrasonic Dissection and Monopolar Electrocautery in Single-Incision Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair

单孔腹腔镜全腹膜外腹股沟疝修补术中超声切割与单极电灼的探索性随机对照试验

2026-01-010
PRE
Defining Low Muscle Mass in Cancer Patients: Sex-Specific Computed Tomography-Derived Cutoff Values and Survival Impact—A Multicenter Cohort Study

定义癌症患者低肌肉量的标准:基于性别特定的计算机断层扫描导出的截断值及其对生存期的影响——一项多中心队列研究

2025-09-190
PRE
Postoperative chemotherapy after conversion surgery for clinical stage IV gastric cancer: a propensity score-matched analysis

转化手术后临床IV期胃癌的术后化疗:一项倾向性评分匹配分析

2025-08-270
OA
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902)

新辅助多西他赛、奥沙利铂和S-1疗法用于大体积III型或IV型胃癌患者的短期疗效:一项多中心II期研究(OGSG1902)的短期结果

2025-03-310
PRE
Robotic and laparoscopic gastrectomy for gastric cancer: comparative insights into perioperative performance and three-year survival outcomes

机器人和腹腔镜胃癌切除术: 对围手术期性能和三年生存结果的比较见解

2025-02-260
PRE
A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic cancer
SURGERY
IF2.7
2024-10-016
PRE
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

Nivolumab联合化疗治疗HER2-negative,既往未治疗,不可切除,晚期或复发性胃/胃食管交界癌患者: 吸引-4随机,双盲,安慰剂对照,3期临床试验的3年随访

2024-08-201
OAAI
Survival Impact of Inflammation-based Prognostic Scores in Metastatic or Unresectable Esophageal Cancer Treated With Pembrolizumab Plus Chemotherapy
2024-06-032
PRE
Risk factors for abdominal surgical infectious complications after distal gastrectomy for gastric cancer: A post-hoc analysis of a randomized controlled trial (JCOG0912)

远端胃癌切除术后腹部手术感染性并发症的危险因素: 一项随机对照试验 (JCOG0912) 的事后分析

EJSO
IF2.9
2024-03-011
OAAI